Browse WDR33

Summary
SymbolWDR33
NameWD repeat domain 33
Aliases FLJ11294; WDC146; NET14; WD repeat-containing protein 33; WD repeat-containing protein WDC146; pre-mRNA 3' e ......
Chromosomal Location2q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF00400 WD domain
Function

Essential for both cleavage and polyadenylation of pre-mRNA 3' ends.

> Gene Ontology
 
Biological Process GO:0006301 postreplication repair
GO:0006379 mRNA cleavage
GO:0006397 mRNA processing
GO:0007283 spermatogenesis
GO:0048232 male gamete generation
GO:0090305 nucleic acid phosphodiester bond hydrolysis
GO:0090501 RNA phosphodiester bond hydrolysis
Molecular Function -
Cellular Component GO:0005581 collagen trimer
GO:0005847 mRNA cleavage and polyadenylation specificity factor complex
GO:0005849 mRNA cleavage factor complex
> KEGG and Reactome Pathway
 
KEGG hsa03015 mRNA surveillance pathway
Reactome R-HSA-109688: Cleavage of Growing Transcript in the Termination Region
R-HSA-74160: Gene Expression
R-HSA-112296: Post-Elongation Processing of Intron-Containing pre-mRNA
R-HSA-112297: Post-Elongation Processing of Intronless pre-mRNA
R-HSA-76044: Post-Elongation Processing of the Transcript
R-HSA-72203: Processing of Capped Intron-Containing Pre-mRNA
R-HSA-75067: Processing of Capped Intronless Pre-mRNA
R-HSA-77595: Processing of Intronless Pre-mRNAs
R-HSA-73857: RNA Polymerase II Transcription
R-HSA-73856: RNA Polymerase II Transcription Termination
R-HSA-72202: Transport of Mature Transcript to Cytoplasm
R-HSA-159231: Transport of Mature mRNA Derived from an Intronless Transcript
R-HSA-159234: Transport of Mature mRNAs Derived from Intronless Transcripts
R-HSA-72187: mRNA 3'-end processing
R-HSA-72172: mRNA Splicing
R-HSA-72163: mRNA Splicing - Major Pathway
Summary
SymbolWDR33
NameWD repeat domain 33
Aliases FLJ11294; WDC146; NET14; WD repeat-containing protein 33; WD repeat-containing protein WDC146; pre-mRNA 3' e ......
Chromosomal Location2q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between WDR33 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolWDR33
NameWD repeat domain 33
Aliases FLJ11294; WDC146; NET14; WD repeat-containing protein 33; WD repeat-containing protein WDC146; pre-mRNA 3' e ......
Chromosomal Location2q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of WDR33 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.63 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolWDR33
NameWD repeat domain 33
Aliases FLJ11294; WDC146; NET14; WD repeat-containing protein 33; WD repeat-containing protein WDC146; pre-mRNA 3' e ......
Chromosomal Location2q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of WDR33 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0430.786
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0340.984
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0990.938
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0050.981
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0340.99
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0320.993
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1140.75
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0850.959
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.130.944
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1870.882
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.80.657
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0090.833
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of WDR33 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.3014.30.196
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103200201
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.84.110.70.0828
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.85.19.70.199
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.55.93.61
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.49.16.31
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolWDR33
NameWD repeat domain 33
Aliases FLJ11294; WDC146; NET14; WD repeat-containing protein 33; WD repeat-containing protein WDC146; pre-mRNA 3' e ......
Chromosomal Location2q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of WDR33. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolWDR33
NameWD repeat domain 33
Aliases FLJ11294; WDC146; NET14; WD repeat-containing protein 33; WD repeat-containing protein WDC146; pre-mRNA 3' e ......
Chromosomal Location2q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of WDR33. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by WDR33.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolWDR33
NameWD repeat domain 33
Aliases FLJ11294; WDC146; NET14; WD repeat-containing protein 33; WD repeat-containing protein WDC146; pre-mRNA 3' e ......
Chromosomal Location2q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of WDR33. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolWDR33
NameWD repeat domain 33
Aliases FLJ11294; WDC146; NET14; WD repeat-containing protein 33; WD repeat-containing protein WDC146; pre-mRNA 3' e ......
Chromosomal Location2q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of WDR33 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolWDR33
NameWD repeat domain 33
Aliases FLJ11294; WDC146; NET14; WD repeat-containing protein 33; WD repeat-containing protein WDC146; pre-mRNA 3' e ......
Chromosomal Location2q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between WDR33 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolWDR33
NameWD repeat domain 33
Aliases FLJ11294; WDC146; NET14; WD repeat-containing protein 33; WD repeat-containing protein WDC146; pre-mRNA 3' e ......
Chromosomal Location2q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting WDR33 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.